Business Context and Reporting Period
This Form 8-K was filed by Neoleukin Therapeutics, Inc. (trading symbol: NLTX) on October 26, 2022. The report addresses a regulatory notice received from the Nasdaq Stock Market regarding the company's compliance with continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the notice: the closing bid price for the Company's common stock fell below $1.00 per share for 30 consecutive business days.
Material Changes
The material event reported is the receipt of a Notice of Delisting or Failure to Satisfy a Continued Listing Rule from Nasdaq. The company is currently non-compliant with Nasdaq Listing Rule 5550(a)(2) due to the sustained low stock price. This notice has no immediate effect on the listing status but initiates a compliance timeline.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has an initial 180-day compliance period ending April 24, 2023, to regain compliance.
- Requirements: To regain compliance, the closing bid price must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to the deadline.
- Contingencies: If compliance is not met by April 24, 2023, the company may be eligible for an additional 180-day grace period if it applies to transfer listing to the Nasdaq Capital Market. This would require meeting market value standards and potentially effecting a reverse stock split.
- Risks: There is no assurance the company will regain compliance. Failure to do so could result in delisting. The company is considering actions to respond but has made no decisions at this time.
Investor Verification Checklist
- Verify the current closing bid price of NLTX common stock to assess progress toward the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or transfer to the Nasdaq Capital Market.
- Check for subsequent filings regarding the company's appeal rights if delisting is threatened after the compliance period.
- Review the company's broader financial health in recent 10-K or 10-Q filings, as this 8-K does not contain operational financial data.